Israel’s Health Ministry said on Tuesday it had found the small number of heart inflammation cases observed mainly in young men who received Pfizer’s (PFE.N) COVID-19 vaccine in Israel were likely linked to their vaccination.
Pfizer said in a statement that it was aware of the Israeli observations of myocarditis and said no causal link to its vaccine had been established.
It said adverse events are thoroughly reviewed and Pfizer meets regularly with the Vaccine Safety Department of the Israeli Ministry of Health to review data.
In Israel, 275 cases of myocarditis were reported between December 2020 and May 2021 among more than 5 million vaccinated people, the ministry said in disclosing the findings of a study it commissioned to examine the matter.
Most patients who experienced heart inflammation spent no more than four days in the hospital and 95% of the cases were classified as mild, according to the study, which the ministry said was conducted by three teams of experts.
The study found “there is a probable link between receiving the second dose (of Pfizer) vaccine and the appearance of myocarditis among men aged 16 to 30,” it said in a statement. According to the findings, such a link was observed more among men aged 16 to 19 than in other age groups.
A U.S. Centers for Disease Control and Prevention (CDC) advisory group last month recommended further study of the possibility of a link between myocarditis and mRNA vaccines, which include those from Pfizer and Moderna Inc. Read More » “Israel sees probable link between Pfizer vaccine and myocarditis cases”
The post “Israel sees probable link between Pfizer vaccine and myocarditis cases” appeared first on Reuters.com